Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment

Details for Australian Patent Application No. 2006269555 (hide)

Owner Pfizer Inc. Coley Pharmaceutical Group, Inc.

Inventors Gomez-Novarro, Jesus; Krieg, Arthur M.; Jungnelius, Jarl Ulf Birger; Hanson, Douglas C.; Readett, David Robert John

Agent Davies Collison Cave

Pub. Number AU-A-2006269555

PCT Pub. Number WO2007/008463

Priority 60/697,082 07.07.05 US

Filing date 30 June 2006

Wipo publication date 18 January 2007

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

A61K 39/39 (2006.01) Medicinal preparations containing antigens or antibodies - characterised by the immunostimulating additives, e.g. chemical adjuvants

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

28 February 2008 PCT application entered the National Phase

  PCT publication WO2007/008463 Priority application(s): WO2007/008463

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006269566-Method for predicting the best and worst in a set of non-unique solutions

2006269550-Low viscosity, unstable waterin-silicone emulsion cosmetic compositions and methods of use thereof